Neola Medical

31/08/2026

Neola Medical has been granted a new U.S. design patent protecting the graphical user interface of Neola®.

“Strong intellectual property protection is an important strategic asset as we continue the development of Neola® towardfuture market introduction,” says Hanna Sjöström, CEO of Neola Medical.

26/08/2026

⭐️In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the key milestones from Neola Medical’s Q2 2026 report.

Watch the full interview here: https://player.vimeo.com/video/1219894021

21/08/2026

☀️ Catch up on Neola Medical’s Q2 2026 progress.
In our latest report presentation, CEO Hanna Sjöström share reflections on our clinical progress, strengthened financing and sharpened strategic focus, while CFO David Folkesson presents the Q2 financial results.

Watch the presentation and Q&A session here:

On the 20th of August at 10.00 CET, CEO Hanna Sjöström and CFO Davi...

20/08/2026

Q2 report 2026 now published! CEO Hanna Sjöström is highlighting clinical progress, strengthened financing and sharpened focus.

Read the full report here: https://lnkd.in/dzTZWDAp

12/08/2026

Neola Medical invites to presentation of the Q2 report 2026 with CEO Hanna Sjöström and CFO David Folkesson.

Watch the presentation here:
https://youtube.com/live/r5ppKjIvrec?feature=share

22/06/2026

Neola Medical’s rights issue was subscribed to approximately 70 percent, providing the company with approximately SEK 32.5 million before issue costs. The capital will support the continued development of Neola® as the company advances its clinical, regulatory and commercial preparations ahead of the journey toward market launch.

“Thank you to our shareholders, guarantors and new investors for your participation and support. Your commitment strengthens our ability to continue advancing Neola® and our mission to improve care for preterm born babies,” says Hanna Sjöström, CEO of Neola Medical.

16/06/2026

🫁 Imorgon onsdag den 17 juni 2026 är sista dagen att teckna företrädesemissionen i Neola Medical!
Läs mer på nyemissioner.se och teckna redan idag.

https://nyemissioner.se/nyheter/neola-medical-tar-sikte-pa-usa-efter-lyckad-klinisk-studie

Medicinteknikbolaget Neola Medical närmar sig en avgörande fas i utvecklingen av sin produkt för övervakning av för tidigt födda barns lungor. Efter att nyligen ha genomfört sin första kliniska studie på för tidigt födda barn riktas nu fokus mot den amerikanska marknaden, där bolaget ser...

09/06/2026

🫁Redeye Interview: Neola Medical’s rights issue with CEO Hanna Sjöström

In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström presents the upcoming rights issue accelerating the journey towards FDA approval and market launch.

Watch the full interview here: https://player.vimeo.com/video/1199757772

Access additional insights from Redeye here: https://www.redeye.se/company/neola-medical

08/06/2026

CEO Hanna Sjöström will deliver a live, on-site presentation at Aktiedagarna in Stockholm on June 10, 2026, at 08:50 CET at Birger Jarl Konferens.
“Neola Medical is entering an important next phase, building on positive safety results from our first clinical pilot study and a sharpened focus on lung collapse detection. At Aktiedagarna, I look forward to presenting our continued preparations toward the U.S. market and how the ongoing rights issue supports this next step,” says Hanna Sjöström, CEO of Neola Medical.

If unable to attend in Stockholm, the presentation will be streamed online at the following link: https://lnkd.in/dSrRd3Sc

The presentation will also be accessible for viewing afterward at www.neolamedical.com

19/05/2026

📣 Neola Medical today released the Q1 report of 2026! 📘👶🏻
“The first quarter of 2026 marked an important milestone for Neola Medical with the completion of enrollment and final results from our first clinical study on preterm born babies. The study represented the first real-world use of Neola® in its intended patient population within neonatal intensive care and confirmed a favorable safety profile across the studied patient population, including very low birth weight preterm born babies.”, says CEO Hanna Sjöström